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Abstract
Development of molecular diagnostics that can reliably differentiate amongst different subtypes of brain tumors
is an important unmet clinical need in postgenomics medicine and clinical oncology. A simple linear formula
derived from gene expression values of four genes (GFAP, PTPRZ1, GPM6B, and PRELP) measured from cDNA
microarrays (n¼ 35) have distinguished glioblastoma and meningioma cases in a previous study. We herein
extend this work further and report that the above predictor formula showed its robustness when applied to
Affymetrix microarray data acquired prospectively in our laboratory (n¼ 80) as well as publicly available data
(n¼ 98). Importantly, GFAP and GPM6B were both retained as being significant in the predictive model upon
using the Affymetrix data obtained in our laboratory, whereas the other two predictor genes were SFRP2 and
SLC6A2. These results collectively indicate the importance of the expression values of GFAP and GPM6B genes
sampled from the two types of microarray technologies tested. The high prediction accuracy obtained in these
instances demonstrates the robustness of the predictors across microarray platforms used. This result would
require further validation with a larger population of meningioma and glioblastoma cases. At any rate, this
study paves the way for further application of gene signatures to more stringent biopsy discrimination chal-
lenges.
Introduction
Compatibility of gene expression values obtainedfrom different microarray technology platforms for a
given biological condition (e.g., in cancer tissue) has been
subject to intensive research and debates (Borozan et al., 2008;
Liu et al., 2008). In the context of clinical oncology and pre-
dictive medicine, such a discussion concerns the clinical va-
lidity of outcomes generated from high throughput omics
technologies (Sun and Yang, 2006; Wang and Chao, 2007).
Gene expressionmicroarrays produce a substantial amount of
data that must be reproducible across diverse microarray
technologies and across different centers, to be of use in
clinical trials and in routine diagnostic medicine (Sun and
Yang, 2006; Wang and Chao, 2007).
Over the past several years, studies have demonstrated
nonsignificant variation of gene expression values for a de-
termined biological condition, across microarray experiments
using various technologies (Bosotti et al., 2007; Hwang et al.,
2004; Shi et al., 2006). Nonetheless, development of prediction
models to discriminate between tumor types by using gene
expression data from different microarray technologies does
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not seem to have been addressed. Such an issue appears to be
crucial, prior to implementation in clinical trials of prediction
models derived from microarray data (Sun et al., 2006; Wang
et al., 2007).
In a previous work, we were able to distinguish glioblas-
toma multiforme (Gbm, n¼ 17) and meningothelial menin-
gioma (Mm, n¼ 18) biopsies through a simple linear equation
derived from the expression values of four genes (GFAP,
PTPRZ1, GPM6B, and PRELP), obtained from single-labeling
cDNA microarray experiments (Castells et al., 2009). We take
now this proof-of-principle approach one step further to in-
vestigate the robustness of the predictor developed earlier.
For this goal, we evaluated the formula by prediction of three
datasets, for which the gene expression values were obtained
from Affymetrix microarray experiments. The two first da-
tasets (total n¼ 80) were prospectively acquired at our labo-
ratory, whereas the last dataset corresponded to the publicly
available data (n¼ 98).
In the present study, we evaluated whether the four genes
identified previously from the cDNA microarray-based data
were also selected when the predictor was generated from
Affymetrix data acquired in our laboratory (total n¼ 80). That
is, we developed a stepwise procedure on our Affymetrix
dataset to select four genes that fitted an optimal predictor for
Gbs and Mgs. Subsequently, we evaluated whether this pre-
dictor could discriminate Gbs and Mgs from publicly avail-
able and cDNA microarray data. In doing so, we aimed to
verify whether the four genes mentioned above could be se-
lected to discriminate glioblastomas (Gbs) and meningiomas
(Mgs) when using gene expression values from another type
of microarray technology.
Materials and Methods
Collection, storage and histopathology analysis
of samples prospectively acquired
Collection of biopsies was carried out at different hospitals
from the Barcelona metropolitan area through the European
Union-funded eTUMOUR (http:==www.etumour.net) and
HealthAgents (http:==www.healthagents.net) projects and
the Spanish-funded MEDIVO2 project.
A total of 77 biopsies were collected from the Hospital
Universitari de Bellvitge (L’Hospitalet de Llobregat), 2 biopsies
from the Hospital Universitari Germans Trias i Pujol (Badalona),
and 1 biopsy from the Hospital Sant Joan de De´u (Esplugues de
Llobregat). Among the 80 biopsies included in this study, 49
were glioblastomas [Gb(s), including 1 gliosarcoma] and 31
were meningiomas [Mg(s), including 22 of meningothelial
subtype, 3 of fibrous subtype, 3 of psammomatous subtype,
and 3 transitional meningiomas]. The full study protocol was
approved by the local Ethics Committees and informed con-
sent was obtained from all patients.
An aliquot of tumor was snap frozen in liquid nitrogen
until RNA isolation. Another aliquot was fixed in 4% buffered
formalin and embedded in paraffin. For routine histological
examination 4mm-thick sections were stained with hematox-
ylin and eosin (HE). Both, the WHO 2000 and 2007 Nervous
System Classification criteria (Kleihues and Cavenee, 2000;
Louis et al., 2007) were used for diagnosis, because biopsies
were collected from 2004 until 2008.
RNA isolation
Total RNA from frozen biopsies stored in liquid nitrogen
was isolated following the procedure indicated by the
manufacturer using the mirVana RNA isolation kit (Ambion-
Applied Biosystems, Austin, TX, USA). RNA was character-
ized using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). Absence of protein
contamination was monitored by the 260 nm=280 nm ratio of
absorbance, and sampleswith a ratio ranging between 1.6 and
2.0 were accepted for further processing, as agreed in the
consensus protocols for data acquisition in the eTUMOUR
project. Integrity of the RNA was assessed by using the cap-
illary electrophoretic system 2100 Bioanalyzer (Agilent, Santa
Clara, CA, USA). Only samples producing a 28S=18S ratio
equal or higher than 1.2 or an RNA integrity number (RIN)
number equal or higher than 6 were used for further analysis.
Labeling and hybridization onto HG-U133
plus 2.0 Affymetrix microchips
The procedure described in this section was performed at
the Affymetrix core facility of the Institut de Recerca de la Vall
d’Hebron (Barcelona). Labeling was performed using the One-
Cycle Target Labeling and Control Reagents kit (Affymetrix,
Santa Clara, CA, USA). The starting material for the labeling
protocol ranged from 0.3 to 5mg of total RNA and the re-
sulting labeled cRNAs were hybridized onto the HG-U133
plus 2.0 GeneChip. Fluorescence images were obtained by
scanning the microchips with the software provided with the
GeneChip Scanner 3000.
Publicly available data
The raw expression data of 67 glioblastomas (GDS1976)
and 31 meningiomas (GSE9438) were downloaded from
the Gene Expression Omnibus (GEO) repository (http:==
www.ncbi.nlm.nih.gov=sites=entrez?db¼ gds). The expres-
sion profile for glioblastomas (Gb) had been obtained from the
HG-U133A and B Affymetrix microchips. In contrast, the
expression profile for meningiomas (Mgs) had been obtained
from the HG-U133 plus 2.0 Affymetrix microchip.
Normalization and pattern recognition methods
Predictor from cDNA microarray data and validation on
Affymetrix data. Background correction and normalization
of Affymetrix data was performed using the robust multi-
array average (RMA) method available in the affy package
at the Bioconductor repository (www.bioconductor.org). As
eTUMOUR has been a prospective project, the 80 cases used
in this work were available in two batches. First, 32Gbs and
12Mgs (UAB1 dataset) and second, 17Gbs and 19Mgs (UAB2
dataset) became available. Each batch was separately nor-
malized. Also, the two types of Affymetrix microchips from
publicly available data were separately normalized using
RMA. This was a must, because the number of probesets in
eachmicrochip is different. As described in our previouswork
(Castells et al., 2009), cDNA microarray data was normalized
using the average reference loess (Edwars, 2003).
On the other hand, the gene expression values of the four
discriminant genes composing the prediction formula (Eq. 1)
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derived from cDNA microarray data were used to compute
the discriminant scores in Affymetrix datasets as described in
our previous work (Castells et al., 2009).
DSC¼  0:394GFAP 0:397PTPRZ1
 0:397GPM6Bþ 0:365PRELP (1)
Predictor from Affymetrix data acquired in our laboratory
and validation on publicly available Affymetrix and cDNA
microarray data. We normalized cDNA microarray and
publicly available Affymetrix data as described in the previ-
ous subsection. In contrast, datasets UAB1 and UAB2 were
normalized together using the RMA method, because both
datasets were used to develop a predictor for Gbs and Mgs.
The use of a dataset composed of 80 cases (UAB dataset) could
provide a better estimation of the prediction accuracy in the
training. The development of a predictor from datasets UAB1
and UAB2 consisted in randomly splitting the whole dataset
(80 cases) in two-thirds for training and one-third for test. We
maintained the frequency of each tumor type for both training
and test sets and performed 200 times the random splitting.
At each iteration, only training data was used to assess the
statistical difference of each probeset between Gbs and Mgs.
We only used those 12,145 probesets that represented genes
present in the cDNA microarray (CNIO Oncochip, ArrayEx-
press acc. no. A-MEXP-261). We computed p-values for the
probesets considered using the rank-based Wilcoxon test.
These p-values were corrected to reduce the false discovery
rate and we obtained the so-called q-values (Storey and Tib-
shinni, 2003). Among probesets with q-value lower than 0.05,
the four probesets with highest absolute value of the dif-
ference of fluorescence intensity between Gbs and Mgs
{abs[mean (Gbs)-mean(Mgs)]} were selected to fit a predictor
based on linear discriminant analysis (LDA). We used the
LDA algorithm to generate the predictors, because in a pre-
liminary yet unpublished work of our laboratory we tested
various algorithms (dLDA, k-nearest neighbor, support vec-
tor machine, and random Forest) for prediction of four types
of human brain tumors (meningioma, glioblastoma, ana-
plastic glioma, and low grade glioma). LDA was the one that
provided the highest accuracy in all pairwise comparisons.
The LDA predictor was used to predict those cases left apart
for test purposes.
The four genes that were most frequently selected across
the 200 iterations were used to generate an LDA predictor
using the whole dataset (n¼ 80).
Results
Validation of the predictor obtained from
cDNA microarray data on Affymetrix data
We evaluated the Affymetrix probesets that correspond to
the four genes described (GFAP, PTPRZ1, GPM6B, and
PRELP). The GFAP, PTPRZ1, GPM6B, and PRELP genes are
represented in the HG-U133 plus 2.0 microchip by 3, 1, 6, and
4 probesets, respectively. We selected the probeset for which
the accession number and=or RefSeq number coincided with
the one present in the annotation file of the cDNAmicroarray
(CNIO Oncochip). We found coincidence for probeset
‘‘203540_at’’ of GFAP and ‘‘204223_at’’ of PRELP. In contrast,
there was not a clear correspondence for GPM6B between the
accession numbers provided by Affymetrix and the ones
provided by the Oncochip’s manufacturers. For this reason,
we selected the probeset of GPM6B for which we could find
a known protein using the accession number provided by
Affymetrix. As a result, we selected the ‘‘203540_at’’ (GFAP),
‘‘204469_at’’ (PTPRZ1), ‘‘209170_s_at’’ (GPM6B), and
‘‘204223_at’’ (PRELP) probesets (see Table 1).
From the 80 locally accrued cases and hybridized onto
Affymetrix microchips, a subset composed of 44 samples
(32Gbs and 12Mgs) was analyzed first [Fig. 1A]. As the
prediction formula (Eq. 1) had been derived from cDNA mi-
croarray data (Castells et al., 2009), this first subset study was
Table 1. Affymetrix Probesets Representing the 4 Genes of the Prediction Gbm=Mm Formula (Eqs. 1 and 2)
Gb=Mg ratio
Accession
number
Probeset
Affymetrix
Gene
symbol
Locus
link UniGene
Affymetrix
eTUMOUR
UAB1
Affymetrix
eTUMOUR
UAB2
Affymetrix
Pubmed
Sequence
mRNA
length (bp)
Sequence
protein
length (aa)
NM_002055 203540_at GFAP 2670 Hs.514227 40.12 327.78 37.65 3081 432
AL133013 229259_at GFAP 2670 Hs.514227 51.66 46.31 27.00 3279 438
NM_002851 204469_at PTPRZ1 5803 Hs.489824 156.52 544.20 125.81 8169 2,314
AI419030 209167_at GPM6B 2824 Hs.495710 58.90 57.53 28.19 458 —
AW148844 209168_at GPM6B 2824 Hs.495710 74.86 46.35 36.59 415 —
N63576 209169_at GPM6B 2824 Hs.495710 72.07 60.04 25.41 396 —
AF016004 209170_s_at GPM6B 2824 Hs.495710 68.16 53.63 23.93 1642 265
NM_002725 204223_at PRELP 5549 Hs.632481 0.084 0.069 0.096 5833 382
AA573140 228224_at PRELP 5549 Hs.632481 0.17 0.14 0.24 470 —
U41344 37022_at PRELP 5549 Hs.632481 0.52 0.45 0.52 924 382
Biological information about the probesets representing the four genes (GFAP, PTPRZ1, GPM6B, and PRELP) selected to compute the
Gbm=Mm formula is depicted. From left to right, the accession number, the Affymetrix probeset, the gene symbol, the locus link, and
the unigene identifers are given. The next three columns are the Gb=Mg expression ratio for each Affymetrix dataset. Finally, the length of the
mRNA sequence that each probeset represents and the length of the corresponding protein are shown. A dash indicates that the protein
sequence is unknown.
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used to fine tune the prediction formula for gene expression
values obtained from Affymetrix microarrays. Accordingly,
the expression values of the four mentioned genes from the
first batch of Affymetrix data (32Gbs and 12Mgs) were used
to derive an optimized LDA formula. As a result, we obtained
a predictor (Eq. 2) that maximized the interclass distance
and minimized the intraclass distance (see Fig. 1B):
DSC¼ 0:0785GFAPþ 0:620PTPRZ1
þ 0:670GPM6Bþ 0:660PRELP (2)
The cutoff point at 0 enables prediction between the two
tumor types, being Gb and Mg for negative and positive
values, respectively. This formula was derived from the
whole dataset UAB1. To provide an estimation of the pre-
diction accuracy of the formula, we performed a leave-one-
out crossvalidation (Dupuy and Simon, 2007). An apparent
100% of prediction accuracy for a new sample was estimated
from dataset UAB1.
Furthermore, to obtain the discriminant score (DSC) for a
new sample, the GFAP, PTPRZ1, GPM6B, and PRELP values
must be standardized using the mean (C) and the variance (S)
estimated for each probeset from the dataset UAB1:
C(GFAP, PTPRZ1, GPM6B, PRELP)
¼ (8:904749, 7:786328, 9:182813, 7:596874)
S(GFAP, PTPRZ1, GPM6B, PRELP)
¼ (3:702787, 3:728053, 3:094604, 1:735198)
Standardization was performed for each probeset by
combining the mean, the variance, and the fluorescence value
of each probeset normalized (n) using RMA:
GFAP¼ (n(GFAP)C(GFAP))=S(GFAP)
PRELP¼ (n(PRELP)C(PRELP))=S(PRELP)
Such a computation increased the interclass distance and
reduced the intraclass distance of both the initial UAB1 and
the second UAB2 dataset composed of 17Gbs and 19Mgs (see
Fig. 1B). Furthermore, the adjusted formula fully predicted
the class of the Pubmed dataset composed of 67Gbs and
31Mgs, whose gene expression profile was publicly available
at the GEO data repository (see Fig. 1B). As a remark, the gene
expression profile of the 31Mgs from the GEO repository
(GSE9438) was obtained using the HG-U133 plus 2.0 Affy-
metrixmicrochip. In contrast, the gene profiles of the 67Gbs in
dataset GDS1976 were obtained using the HG-U133A and B
Affymetrix microchips. At any rate, a 100% of correct pre-
diction was obtained for all samples tested.
Development of a predictor based on Affymetrix data
acquired in our laboratory and validation on publicly
available Affymetrix and cDNA microarray data
The development of a predictor from the UAB dataset
(n¼ 80) was based in an iterative process. Cases were split
200 times into a group of training (two-thirds of cases) and a
group of test (one-third of cases). Statistical difference be-
tween Gbs and Mgs was only computed in training samples.
At each iteration, we computed the difference between the
average of fluorescence intensity between Gbs and Mgs for
each probeset. As the discrimination capacity would arise
either from a positive or a negative difference, we computed
the absolute value of such differences {abs[mean(Gbs)-
mean(Mgs)]}. To fit the LDA predictor, we selected the four
probesets that displayed the highest absolute difference and
a q-value lower than 0.05. We estimated the prediction ac-
curacy as the average obtained from the test samples across
the 200 iterations. We obtained 99.8% prediction accuracy,
99.75% sensitivity, 99.84% specificity, and an interval of
prediction from 90–100%. Across the 200 iterations, only
seven different probesets were selected to fit the LDA pre-
dictors. Interestingly, the third and fourth most selected
probesets corresponded to GFAP and GPM6B (see Supple-
mentary Table 1). Moreover, the first and second most se-
lected probesets corresponded to the same gene: SFRP2. We
selected to compute a final LDA predictor the four most
selected probesets that corresponded to a unique gene:
SFRP2, GFAP, GPM6B, and SLC6A2. That is, we only used
for the LDA predictor the most selected probeset of SFRP2
across training. We were forced to do this selection because
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FIG. 1. Prediction of Affymetrix-based gene profile for Gbs
and Mgs. (A) Robustness of the developed formula (Eq. 1)
using cDNA microarrays and based on four genes (GFAP,
PTPRZ1, GPM6B, and PRELP), was assessed by prediction
of 32Gb and 12Mg cases, for which the gene profile was
obtained from Affymetrix microchips. Solid symbols denote
Gbs and empty symbols indicate Mgs. Round symbols cor-
responds to cDNA microarrays-hybridized cases (17Gbms
and 18Mms) used in reference (Castells, 2009). Squares in-
dicate the first batch of Affymetrix microchips-hybridized
samples (32Gbs and 12Mgs, UAB1 dataset). (B) This figure
displays discriminant values obtained from Equation 2. A
higher interclass distance and lower intraclass distance than
inA can be seen. The additional Affymetrix cases (17Gbs and
19Mgs, UAB2 dataset) are represented by triangles and the
publicly available data (67Gbs and 31Mgs, Pubmed dataset)
symbolized by rhombi. Along the y axis, the discriminant
score (DSC) of each sample is depicted, whereas samples are
arbitrarily distributed along the x-axis.
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we wanted to use this formula for cDNA microarray
data. As in cDNA microarray data there is only a unique
sequence represented for each gene, selection of more
than one probeset from the same gene was meaningless to fit
the predictor. As a result, we generated an LDA predictor
(Eq. 3) using the expression values of the four probesets
mentioned above (see Table 2) and those cases from dataset
UAB1:
DSC¼  0:0070SFRP2þ 0:0633GFAP
þ 1:129GPM6B 0:541SLC6A2 (3)
As described in the previous subsection, the cutoff point at
0 enables prediction between the two tumor types, being Gb
and Mg for negative and positive values, respectively.
As it can be seen in Figure 2A, a full discrimination between
Gbs and Mgs was obtained for datasets UAB1, UAB2, and
publicly available data. However, some Gbs from publicly
available data appeared close to the cutoff point (DSC¼ 0).
For this reason, we generated a new LDA predictor with the
same probesets but using expression values of those cases
from dataset UAB2.
This new LDA predictor (Eq. 4) produced a higher sepa-
ration between Gbs and Mgs than the one from Equration 3
(see Fig. 2B):
DSC¼  0:437SFRP2þ 0:437GFAP
þ 0:262GPM6B 0:486SLC6A2 (4)
To obtain the discriminant score (DSC) for a new sample,
the SFRP2, GFAP, GPM6B, and SLC6A2 values must be
standardized using the mean (C) and the variance (S) esti-
mated for each probeset from the dataset UAB2:
C(SFRP2, GFAP, GPM6B, SLC6A2)
¼ (9:381613, 8:166541, 8:841530, 9:977249)
S(SFRP2, GFAP, GPM6B, SLC6A2)
¼ (3:937627, 4:485970, 3:852770, 2:598600)
Standardization was performed for each probeset by
combining the mean, the variance and the fluorescence value
of each probeset normalized (n) using RMA:
SFRP2¼ (n(SFRP2)C(SFRP2))=S(SFRP2)
SLC6A2¼ (n(SLC6A2)C(SLC6A2))=S(SLC6A2)
To provide an estimation of the prediction accuracy of
the formula, we performed a leave-one-out crossvalidation
Table 2. Affymetrix Probesets Representing the Four Genes of the Prediction Gb=Mg Formula (Eqs. 3 and 4)
Gb=Mg ratio
Accession
number
Probeset
Affymetrix
Gene
symbol
Locus
link UniGene
Affymetrix
eTUMOUR
UAB1
Affymetrix
eTUMOUR
UAB2
Affymetrix
Pubmed
cDNA
UAB
Sequence
mRNA
length (bp)
Sequence
protein
length (aa)
AF311912 223122_s_at SFRP2 6423 Hs.481022 0.032 0.011 0.026 0.212 1,988 295
NM_002055 203540_at GFAP 2670 Hs.514227 42.90 165.89 37.65 412.52 3,081 432
AI419030 209167_at GPM6B 2824 Hs.495710 62.74 49.69 28.19 132.77 458 —
AI025519 205097_at SLC26A2 1836 Hs.302738 0.045 0.038 0.024 0.013 977 —
Biological information about the probesets representing the four genes (SFRP2, GFAP, GPM6B, and SLC6A2) selected to compute the
Gb=Mg formula is depicted. From left to right, the accession number, the Affymetrix probeset, the gene symbol, the locus link, and the
unigene identifers are given. The next three columns are the Gb=Mg expression ratio for each Affymetrix dataset. Finally, the length of
the mRNA sequence that each probeset represents and the length of the corresponding protein are shown. A dash indicates that the protein
sequence is unknown.
−
2
−
1
0
1
2
3
4A
samples
D
SC
−
2
−
1
0
1
2
3B
samples
D
SC
FIG. 2. Predictor for Gbs and Mgs based on Affymetrix
data. (A) Robustness of the developed formula (Eq. 3) using
Affymetrix data from the dataset UAB1 (32Gbs and 12Mgs,
UAB1 dataset) and based on four genes (SFRP2, GFAP,
GPM6B, and SLC6A2), was assessed by prediction of the Af-
fymetrix dataset UAB2 (17Gb and 19Mg cases) and publicly
available data (67Gbs and 31Mgs, Pubmed dataset). Solid
symbols denote Gbs and empty symbols indicate Mgs.
Squares indicate the first batch of Affymetrix microchips-
hybridized samples. The second batch of Affymetrix cases
acquired in our laboratory (UAB2 dataset) is represented by
triangles and the publicly available (Pubmed dataset) data
symbolized by rhombi. (B) This figure displays discriminant
values obtained from Equation 4. A higher interclass distance
than in A can be seen. Round symbols corresponds to cDNA
microarrays-hybridized cases (17Gbms and 18Mms) used in
reference (Castells, 2009). Along the y-axis, the discriminant
score (DSC) of each sample is depicted, whereas samples are
arbitrarily distributed along the x axis.
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(Dupuy and Simon, 2007). An apparent 100% of prediction
accuracy for a new sample was estimated from dataset UAB2.
Discussion
Reproducibility of gene expression values from micro-
array data for a given biological condition across technolo-
gies or platforms is a crucial consideration prior to
evaluating putative predictors of cancer subtypes in a clini-
cal investigation (Sun and Yang, 2006; Wang and Chao,
2007). Previous work has demonstrated the ability of gene
signatures based on microarray data to delineate molecular
types of human brain tumors (Lee et al., 2008; Nutt et al.,
2003; Phillips et al., 2006). However, none of them has pro-
posed a mathematical formula and tested it across different
microarray platforms.
We demonstrate in this work that a prediction formula
derived from single-labeling cDNA microarray (CNIO
Oncochip) data is valid after minor tuning (see Eq. 2) to
predict diagnosis of cases, for which the gene expression
profile is obtained from two types of Affymetrix microchips.
To verify the robustness of the four selected genes from
cDNA microarray data, we evaluated whether these genes
were also selected from Affymetrix data to predict Gbs and
Mgs. For this purpose, we performed a stepwise procedure
on the Affymetrix dataset UAB (n¼ 80). This was based on
splitting samples in two-thirds for training and one-third
for test. We performed 200 iterations and selected in each
iteration the four probe sets with highest absolute value
of the difference between Gb and Mg cases from the
training set {abs[mean(Gbs)-mean(Mgs)]}. As it can be seen
in Supplementary Table 1 and in Table 2, SFRP2, GFAP,
GPM6B, and SLC6A2 were the most selected genes for
classification.
This result corroborates the robustness of the genes se-
lected from cDNA microarray data. That is, GFAP and
GPM6B were selected when Affymetrix data was used to
develop the predictor for Gbs and Mgs. Naturally, it may be
hypothesized that complete robustness would have been
corroborated if the same four genes had been selected. In our
opinion, this would have been unrealistic. We expected that
GFAP was selected, because it is only expressed in glial cells.
In fact, the same probe set of GFAP that we chose when
validating the formula obtained from cDNAmicroarrays was
selected. In contrast, two different probesets of GPM6B
(‘‘209167_at’’ and ‘‘209170_s_at’’) were selected across the 200
iterations (see Supplementary Table 1) and the most selected
one (‘‘209167_at’’) was not the same as the one we selected for
the cDNA microarray formula (‘‘209170_s_at’’). Taking all
this evidence into account, our interpretation is that half of
genes that were selected to fit a predictor using cDNA mi-
croarray data have also been selected when using Affymetrix
data. This may suggest that either the two other genes
(PTPRZ1 and PRELP) are not so relevant for prediction or
there is a difference in the specificity and=or sensitivity be-
tween HG-U133 plus 2.0 Affymetrix microchip and the CNIO
Oncochip. Considering that the manufacture of these two
types of microarrays is very different and that there is a large
amount of genes represented in gene expression microarrays,
both possibilities are plausible.
To our knowledge, this is the first time that a prediction
formula is proposed to predict the diagnosis of two human
brain tumors through an objective method, which is based on
gene expressionmicroarray values of two sets of genes:GFAP,
PTPRZ1, GPM6B, and PRELP; and SFRP2, GFAP, GPM6B,
and SLC6A2. Furthermore, these two sets of genes can predict
Gbs and Mgs, from which the gene expression profile has
been obtained from three different types of microarray (CNIO
Oncochip, HG-U133 plus 2.0 and HG-U133A-B). A 100% of
prediction accuracy can be obtained using both sets of genes
(Eqs. 2 and 4, and Figs. 1B and 2B) when tested in an inde-
pendent dataset. Nonetheless, it may be more realistic to state
that the expected accuracy in a possible future prospective
study should be some value within the interval obtained in
the training process of the predictor. That is, 90–100% when
the predictor is developed from Affymetrix data (see the Re-
sults section), and 70–100% when the predictor is developed
from cDNA microarray data, as described in our previous
work (Castells et al., 2009). Those confidence intervals are due
to the still limited number of cases investigated. Accordingly,
our work provides proof-of-principle to allow future im-
plementation in the clinical routine of objective methods to
identify cancer types based on gene signatures derived from
microarray data. This issue has been addressed during the
preceding years using microarray and other types of data
(Khan et al., 2008; Tate et al., 2006; Tonini and Pistoia, 2006;
Yang et al., 2009), but it remains a matter still in discussion
(Sotiriou and Piccart, 2007).
Furthermore, an interesting feature of our predictors relies
on the discriminative capacity of the two sets of genes se-
lected. Both sets of genes show a high fold change across all
datasets tested. In the case of cDNA microarray data, the bi-
ological meaning of the four genes selected is more coherent
thanwhen selecting genes fromAffymetrix data. As expected,
GFAP is themain contributor to the capacity of discrimination
of Equation 2 (see Table 1), because it is specifically expressed
in glial cells (Baba et al., 1997; Eng et al., 2000]. Although not
specifically expressed in Gbs, PTPRZ1 shows a high expres-
sion in Gbs compared to Mgs (see Table 1). In addition, sup-
pression of the activity of the PTPRZ1 protein with antibodies
has been proposed as a therapy for Gbs (Muller et al., 2004).
Similarly, the high expression of GPM6B and PRELP in Gb
and Mg, respectively, can be detected along all datasets (see
Table 1). Interestingly, the PRELP gene is a member of the
family of the small leucine rich proteoglycans (SLRPs). Other
members of SLRPs (FMOD, OMD, BGN, and OGN) were
found overexpressed in Mgs when using cDNA microarray
data (Castells et al., 2009). This allows identifying the appar-
ent involvement of this gene family in the biology of Mgs, as
described in our previous work (Castells et al., 2009).
Moreover, GFAP was the second gene most frequently
selected when using Affymetrix data to develop the pre-
dictor for Gbs and Mgs. The gene that encodes the secreted
frizzled-related protein 2 (SFRP2) was the most selected
across training. In our opinion, this suggests that the speci-
ficity of the GFAP probesets represented in Affymetrix mi-
crochips may be lower compared to the full cDNA sequence
of GFAP, which is spotted onto the CNIO Oncochip. Inter-
estingly, GPM6B was the third most selected gene in Affy-
metrix data. This was the same position in which was
ranked when using cDNA microarray data. This indicates
that the expression level of this gene is stable across these
two types of microarray technologies and corroborates its
involvement in the biology of glioblastomas. The solute
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carrier family member 6A2 (SLC6A2) encodes a transporter
of noradrenaline.
In Supplementary Table 1, we describe all probesets that
were selected across the 200 iterations when developing the
predictor using Affymetrix data. That is, we annotated at each
iteration the 100 probesets with the highest absolute value of
the difference of fluorescence intensity between Gbs and Mgs
{abs[mean(Gbs)-mean(Mgs)]} and all probesets selected are
described in Supplementary Table 1. Interestingly, PTPRZ1
displayed on average the 16th highest absolute value of the
difference of fluorescence intensity between Gbs and Mgs.
This would confirm the high expression value of this gene in
glioblastoma, although not high enough to be ranked among
the four genes with highest difference. In contrast, PRELP was
not selected, but osteoglycin (OGN), another member of the
SLRPs family, was selected. This may confirm the apparent
relevance of SLRPs members in the biology of meningiomas
that we detected in cDNA microarray data.
Taken together, our study paves the way for further ap-
plication of gene signatures obtained with different micro-
array platforms to automate more stringent human brain
tumor discrimination challenges.
Conclusions
Our study provides support for the idea that objective
prediction of certain types of human brain tumors using gene
signatures obtained from three types of microarrays is feasi-
ble. This result would require further validation with a larger
population of meningioma and glioblastoma cases. At any
rate, our findings pave the way for further application of gene
signatures obtained with different microarray platforms to
predict more stringent human brain tumor discrimination
challenges.
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